Last update July 17, 2023
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Brincidofovir in other languages or writings:
Main tradenames from several countries containing Brincidofovir in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 13.4 -16.8 | % |
Molecular weight | 562 | daltons |
Protein Binding | > 99 | % |
VD | 17.6 | l/Kg |
pKa | 1.32 | - |
Tmax | 2 - 3 | hours |
T½ | 19.3 (metabolit: 113) | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Brincidofovir is a cidofovir prodrug consisting of cidofovir conjugated to a lipid molecule, that is converted intracellularly to cidofovir. It is used in the treatment of smallpox and its utility against adenoviruses, herpesviruses, CMV, monkeypox virus, and Ebola virus is under investigation. Oral administration once or twice a week.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (FDA 2021, Alvárez 2020) (very high percentage of protein binding, moderately high molecular weight and very wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk, although its high lipophilicity could increase it.
Its very low oral bioavailability (FDA 2021) makes it difficult for it to pass to the infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period in which there may be greater intestinal permeability.
Its side effects are rare and mild. (FDA 2021)
t has been used in young infants. (Chan 2021, London 2020)
It is considered a potential human carcinogen. (FDA 2021)
See below the information of these related products: